公开(公告)号：US20240294539A1

公开(公告)日：2024-09-05

申请号：US18626788

申请日：2024-04-04

申请人： Bayer Aktiengesellschaft

发明人： Thomas HIMMLER ,  Peter BRUECHNER ,  Werner LINDNER ,  Julia Johanna HAHN ,  Wahed Ahmed MORADI ,  Reiner FISCHER ,  Michael DOCKNER

IPC分类号： C07D491/113 ,  C07C229/48 ,  C07C233/52 ,  C07D209/54

CPC分类号： C07D491/113 ,  C07C229/48 ,  C07C233/52 ,  C07D209/54 ,  C07C2601/14 ,  C07C2601/16

摘要： The present invention relates to a novel process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols, and to novel intermediates or starting compounds that are passed through or used in the process according to the invention.

公开(公告)号：US12076306B2

公开(公告)日：2024-09-03

申请号：US18144890

申请日：2023-05-09

申请人： Alkermes Pharma Ireland Limited

发明人： Tarek A. Zeidan ,  Scott Duncan ,  Christopher P. Hencken ,  Thomas Andrew Wynn ,  Carlos N. Sanrame

IPC分类号： C07C235/88 ,  A61K31/225 ,  C07C219/08 ,  C07C229/16 ,  C07C233/18 ,  C07C233/91 ,  C07C317/18 ,  C07C317/28 ,  C07D207/06 ,  C07D207/40 ,  C07D209/52 ,  C07D211/06 ,  C07D211/38 ,  C07D295/088 ,  C07D491/113

CPC分类号： A61K31/225 ,  C07C219/08 ,  C07C229/16 ,  C07C233/18 ,  C07C233/91 ,  C07C235/88 ,  C07C317/18 ,  C07C317/28 ,  C07D207/06 ,  C07D207/40 ,  C07D209/52 ,  C07D211/06 ,  C07D211/38 ,  C07D295/088 ,  C07D491/113

摘要： The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

公开(公告)号：US20240246910A1

公开(公告)日：2024-07-25

申请号：US18405058

申请日：2024-01-05

申请人： Sensorium Therapeutics, Inc.

发明人： Jacob M. Hooker ,  Michael S. Placzek

IPC分类号： C07D209/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D475/04 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D519/00 ,  C07F7/18

CPC分类号： C07D209/12 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D475/04 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D495/10 ,  C07D497/10 ,  C07D498/10 ,  C07D519/00 ,  C07F7/1804

摘要： Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

公开(公告)号：US12042541B2

公开(公告)日：2024-07-23

申请号：US18194540

申请日：2023-03-31

申请人： ARBUTUS BIOPHARMA CORPORATION

发明人： Muthiah Manoharan ,  Muthusamy Jayaraman ,  Kallanthottathil G. Rajeev ,  Laxman Eltepu ,  Steven Ansell ,  Jianxin Chen

IPC分类号： A61K47/44 ,  A61K9/127 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/00 ,  A61K39/39 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/28 ,  C07C229/08 ,  C07C229/30 ,  C07C237/16 ,  C07C251/38 ,  C07C251/78 ,  C07C271/12 ,  C07C271/20 ,  C07C323/25 ,  C07D203/10 ,  C07D317/28 ,  C07D317/44 ,  C07D317/46 ,  C07D317/72 ,  C07D319/06 ,  C07D405/12 ,  C07D491/056 ,  C07D491/113 ,  C12N15/11 ,  C12N15/113

CPC分类号： A61K47/44 ,  A61K9/1272 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/00 ,  A61K39/39 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/28 ,  C07C229/08 ,  C07C229/30 ,  C07C237/16 ,  C07C251/38 ,  C07C251/78 ,  C07C271/12 ,  C07C271/20 ,  C07C323/25 ,  C07D203/10 ,  C07D317/28 ,  C07D317/44 ,  C07D317/46 ,  C07D317/72 ,  C07D319/06 ,  C07D405/12 ,  C07D491/056 ,  C07D491/113 ,  C12N15/111 ,  C12N15/113 ,  A61K2039/55555 ,  A61K2039/55561 ,  C12N2310/14 ,  C12N2310/3515 ,  C12N2320/32 ,  Y02A50/30

摘要： The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure




wherein:



R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).

公开(公告)号：US20240116897A1

公开(公告)日：2024-04-11

申请号：US18274864

申请日：2022-01-21

申请人： KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  PINOTBIO, INC.

发明人： Kwang Rok KIM ,  Kwan Young JEONG ,  Hee Jung JUNG ,  Doyoun KIM ,  Junmi LEE ,  Sang Dal RHEE ,  Kyu Myung LEE

IPC分类号： C07D403/12 ,  A61P35/00 ,  C07D235/32 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/10 ,  C07D487/08 ,  C07D491/113 ,  C07D513/04

CPC分类号： C07D403/12 ,  A61P35/00 ,  C07D235/32 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/10 ,  C07D487/08 ,  C07D491/113 ,  C07D513/04

摘要： The present invention relates to a benzothiazole or benzimidazole derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of SIRTUIN 7 protein-related diseases. With excellent inhibitory activity against SIRTUIN 7 protein the derivative can be used for preventing or treating SIRTUIN 7 protein-related diseases.

公开(公告)号：US20240101549A1

公开(公告)日：2024-03-28

申请号：US18257123

申请日：2021-12-16

申请人： AstraZeneca AB

发明人： Jonas BRÅNALT ,  Björn HOLM ,  Maria JOHANSSON ,  Olle KARLSSON ,  Daniel Laurent KNERR ,  Anneli NORDQVIST ,  Robert John SHEPPARD ,  Marianne SWANSON ,  Anna TOMBERG

IPC分类号： C07D417/14 ,  C07D493/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/113 ,  C07D487/10 ,  C07D498/08 ,  C07D495/10 ,  A61P1/16

CPC分类号： C07D417/14 ,  C07D493/10 ,  C07D487/04 ,  C07D491/107 ,  C07D491/113 ,  C07D487/10 ,  C07D498/08 ,  C07D495/10 ,  A61P1/16

摘要： Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

公开(公告)号：US20230150993A1

公开(公告)日：2023-05-18

申请号：US17930352

申请日：2022-09-07

申请人： Merck Patent GmbH ,  Vertex Pharmaceuticals Incorporated

发明人： Henry YU ,  Michael Clark ,  Guy Bemis ,  Micheal Boyd ,  Kishan Chandupatla ,  Philip Collier ,  Hongbo Deng ,  Huijun Dong ,  Warren Dorsch ,  Russell R. Hoover ,  Mac Arthur Johnson, JR. ,  Shashank Kulkarni ,  Marina Penney ,  Steven Ronkin ,  Darin Takemoto ,  Qing Tang ,  Nathan D. Waal ,  Tiansheng Wang ,  David J. Lauffer ,  Pan Li

IPC分类号： C07D413/14 ,  A61P35/00 ,  C07D417/14 ,  C07D491/107 ,  C07D401/14 ,  C07D413/04 ,  C07D491/113 ,  C07D403/04

CPC分类号： C07D413/14 ,  A61P35/00 ,  C07D417/14 ,  C07D491/107 ,  C07D401/14 ,  C07D413/04 ,  C07D491/113 ,  C07D403/04

摘要： The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US11555012B2

公开(公告)日：2023-01-17

申请号：US16677768

申请日：2019-11-08

申请人： Nimbus Artemis, Inc.

发明人： Silvana Marcel Leit de Moradei ,  Eric Therrien

IPC分类号： C07C311/29 ,  C07C311/21 ,  C07D491/113 ,  C07D295/135 ,  C07D333/20 ,  C07D257/04 ,  C07D295/10 ,  C07D205/04 ,  C07D277/34 ,  C07D209/80 ,  C07D231/38 ,  C07D263/32 ,  C07D401/12 ,  C07D413/06 ,  C07D401/04 ,  C07D409/12 ,  C07D213/04

摘要： The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

公开(公告)号：US20230002393A1

公开(公告)日：2023-01-05

申请号：US17620346

申请日：2020-05-20

申请人： BEIJING BENICALL BIOTECH CO., LTD.

发明人： Zhengying Pan ,  Rui Zhang ,  Zude Qi

IPC分类号： C07D487/04 ,  C07D519/00 ,  C07D491/107 ,  C07D491/113

摘要： Disclosed in the present application are a compound of general formula (I) capable of being used as a CDK kinase (in particular, CDK4/6 kinase) inhibitor, and a salt thereof, wherein all variates are defined as the present text. The compound can be used for treating or preventing diseases such as cancer. The present application further relates to a pharmaceutical composition comprising the compound of formula (I).

公开(公告)号：US20220306588A1

公开(公告)日：2022-09-29

申请号：US17693527

申请日：2022-03-14

申请人： Merck Patent GmbH

发明人： Eva-Maria TANZER ,  Kai SCHIEMANN ,  Markus KLEIN

IPC分类号： C07D235/30 ,  A61P35/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D491/048 ,  C07D491/052 ,  C07D491/107 ,  C07D491/113 ,  C07D498/10

摘要： The invention relates to benzimidazole derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.